CAL101
Idiopathic Pulmonary Fibrosis (IPF)
Phase 2Active
Key Facts
About Calluna Pharma
Calluna Pharma is a clinical-stage biotech targeting the root causes of inflammation and fibrosis through a novel platform centered on Damage Associated Molecular Pattern (DAMP) proteins. Its lead asset, an anti-S100A4 antibody (CAL101), is in Phase 2 for IPF, with a broader pipeline targeting oxidized phospholipids (oxPLs) for other chronic inflammatory conditions. The company leverages over 30 years of foundational research from its co-founders and has established a key strategic alliance with Eli Lilly, positioning it to address significant unmet medical needs in large and growing markets.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Axatilimab (SNDX-6352) | Syndax Pharmaceuticals | Phase 2 |
| PIPE-791 | Contineum Therapeutics | Phase 1 |
| LYT-100 (Deupirfenidone) | PureTech Health | Phase 2b |
| Bexotegrast (PLN-74809) | Pliant Therapeutics | Phase 2b |
| TTI-101 | Tvardi Therapeutics | Phase 2 |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| buloxibutid | Vicore Pharma | Phase 2b |
| NLM-001 | Nelum Pharma | Phase 1 |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |